ArticleNeural regeneration research2026
RBAD: The first database dedicated alterations of blood RNA in individuals with Alzheimer's disease and their clinical relevance.
Article in Neural regeneration research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
JOURNAL/nrgr/04.03/01300535-202606000-00070/figure1/v/2026-02-11T151048Z/r/image-tiff Alzheimer's disease-associated transcriptomic landscapes have been defined in brain tissue. However, changes in blood RNA and their clinical relevance remain poorly understood. In this study, we developed an RNA profile based on 1468 blood samples from both human and mouse studies, which include bulk RNA sequencing (RNA-seq), microRNA-seq, and single-cell RNA-seq data. We developed a comprehensive analysis pipeline that conducted over 11 million comparisons and correlations to identify more than 20,000 blood features. With these findings, we established a blood RNA database related to Alzheimer's disease, RNAs in Blood of AD (RBAD, http://www.bioinform.cn/RBAD/ ). Using RBAD, we initially validated well-established Alzheimer's disease-related pathways, including olfactory transduction. We then observed a decrease in both the proportion and functionality of erythroid cells, likely attributed to their elevated CD45 levels and interactions with GZMK+CD8+ T cells. Furthermore, we identified 449 blood RNAs linked to patients' overall survival, along with two mRNAs ( H4C3 and CTU1 ) associated with cognitive decline. In summary, RBAD is the first web-based analysis platform dedicated to investigating blood RNA changes in Alzheimer's disease, and provides valuable insights into potential peripheral biomarkers and pathogenic mechanisms related to Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.